Makrides Maria
Women's and Children's Health Research Institute, Level 7, Clarence Rieger Building, Women's and Children's Hospital, 72 King William Road, North Adelaide, SA 5006, Australia.
Prostaglandins Leukot Essent Fatty Acids. 2009 Aug-Sep;81(2-3):171-4. doi: 10.1016/j.plefa.2009.05.005. Epub 2009 Jun 4.
The metabolic demand for docosahexaenoic acid (22:6 n-3, DHA) is increased during pregnancy because of the extra needs of the fetus, expanded maternal cell mass and placenta. In Western countries maternal dietary DHA intake in pregnancy is low and it is not clear whether adaptive metabolic mechanisms, such as increased DHA synthesis from precursor fatty acids, are capable of meeting the increased DHA need in pregnancy. Consequently randomized controlled trials are important to determine whether additional dietary DHA in pregnancy modifies maternal or infant health outcomes. The available randomized comparisons of DHA supplements vs placebo have assessed outcomes as diverse as maternal depression, infant visual acuity and development, and infant growth and allergy. The outcomes of these trials have not been conclusive because they have often been limited by small sample size. On the other hand, large-scale trials assessing marine oil supplementation with large doses indicate that DHA supplementation in pregnancy is safe.
由于胎儿的额外需求、母体细胞质量的增加以及胎盘的原因,孕期对二十二碳六烯酸(22:6 n-3,DHA)的代谢需求会增加。在西方国家,孕期母体饮食中DHA的摄入量较低,目前尚不清楚适应性代谢机制,如从前体脂肪酸增加DHA合成,是否能够满足孕期增加的DHA需求。因此,随机对照试验对于确定孕期额外补充DHA是否会改变母体或婴儿的健康结局非常重要。现有的DHA补充剂与安慰剂的随机对照比较评估了多种结局,如母体抑郁、婴儿视力和发育、婴儿生长和过敏。这些试验的结果尚无定论,因为它们常常受到样本量小的限制。另一方面,评估大剂量补充海洋油的大规模试验表明,孕期补充DHA是安全的。